This Medical Letter review summarizes a newly approved extended-release, abuse-deterrent capsule formulation of oxycodone for pain management.
The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Once a month, The Medical Letter provides a previously published article to JAMA to be republished.
Previous Publication: The article was published in The Medical Letter on Drugs and Therapeutics. June 20, 2016;58(1497):77-78. It is reprinted here with permission from ©The Medical Letter Inc.
For a free trial subscription to The Medical Letter, go to www.medicalletter.org/tmlj. The Medical Letter—Essential to your practice.
About The Medical Letter: The Medical Letter is a nonprofit organization that publishes biweekly new drug evaluations and treatment recommendations. The Medical Letter does not accept advertisements, gifts, grants, or donations. Financial support comes solely from sales of subscriptions, books, software, continuing education materials, and licenses.
Editors: Mark Abramowicz, MD, President; Gianna Zuccotti, MD, MPH, Vice President and Executive Editor; Jean-Marie Pflomm, PharmD, Editor in Chief